1. molmed s.p.a.
  2. schering n.v./s.a.
  3. actogenix
  4. pfizer, animal health group
  5. sandoz pharma, ltd
  6. genimmune n.v.
  7. Search the database for deliberate release of GM medicinal products

Search the database for deliberate release of GM medicinal products

Displaying 1 - 8 of 8
EU record number Title Company / Sponsor Treated organism Genetic modification
B/BE/21/BVW9 Dossier withdrawn by the notifier ActoGenix Humans V181 is a live attenuated dengue quadrivalent vaccine rDENVΔ30 where the four viral components of V181 (one for each serotype) present a deletion of 30 nucleotides in the 3’ non‐coding region (Δ30)
Only notified under the "contained use" procedure. Dossier submitted on 07/04/2014. A single-center, open-label Phase 1 study to assess safety and medical endoscopic sampling methodology and to characterize the pharmacokinetics of oral doses of AG014 in Healthy Subjects ActoGenix Humans gene expressing certolizumab
Only notified under the "contained use" procedure. Dossier submitted on 08/05/2012. A single-center, open-label Phase 1 study to assess the effect of food/beverage and to characterisze the pharmacokinetics of single and multiple oral doses of AG013 in Healthy Subjects ActoGenix Humans Human Trefoil Factor 1
Only notified under the "contained use" procedure. Dossier submitted on 23/04/2012. Randomized Phase III of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia Molmed S.p.A. Humans -Thymidine Kinase (HSV-Tk) - selection marker
B/BE/07/BVW3 A multi-centre phase I study to evaluate the safety and tolerability of a heterologous prime-boost vaccination with INX102-3697 HBV pDNA/INX102-0557 HBV MVA in healthy volunteers and HBeAg+ chronic hepatitis patients GENimmune N.V. Humans Hepatitis B virus polyepitope gene
B/BE/04/BV1 Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats Pfizer, Animal Health Group cats gene for the env glycoprotein or gene for the gag protein of the Feline immunodeficiency virus (FIV)
Only notified under the "contained use" procedure. Dossier submitted on 11/07/2002. A European and Canadian multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 in patients with stable angina Schering N.V./S.A. Humans human FGF-4
Only notified under the "contained use" procedure. Dossier submitted on 02/01/1996. Gene therapy for the treatment of glioblastoma multiforme with in vivo tumor transduction with the herpes simplex thymidine kinase gene /ganciclovir system Sandoz Pharma, LTD Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)